NTR collector advocates regular yoga practice for govt employees
Vijayawada: NTR district collector Dr G Lakshmisha suggested that govt employees should adopt yoga and make it an integral part of their lives to overcome work-related stress, maintain a healthy work-life balance, and achieve positive outcomes in life.
As part of the month-long Yogandhra awareness campaign, the NTR district's Ayush department, in association with the Vijayawada Municipal Corporation (VMC), conducted a special yoga camp for govt employees near Sarada College on BRTS Road. Dr Lakshmisha, along with employees and employee union leaders, performed various yoga asanas during the event on Sunday.
On the occasion, he urged employee union leaders to explain the benefits of yoga to all employees and encourage them to regularly practice yoga at govt offices. He said that yoga strengthens both the physical and mental health of individuals. He added that the district administration aims to train 15 lakh people in yoga ahead of International Yoga Day, which would be observed on June 2. Dr Lakshmisha urged the cooperation of employees' union JAC leaders in achieving this target.
Meanwhile, APNGO Association state secretary A Vidya Sagar announced financial assistance of Rs 10,000 to yoga trainer B Sireesha, who had trained the employees in various yoga asanas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
26 minutes ago
- Hindustan Times
Huawei Band 10 with 1.47-inch AMOLED display and 100 preset workout modes launched in India
Huawei has launched the Huawei Band 10 in India on Friday as part of its new range of smart wearable devices. Huawei Band 10 features a 1.47-inch AMOLED rectangular display with support for Always On Display. This smart band offers up to 14 days of battery life and comes in two case materials: polymer and aluminium alloy. The device tracks various health metrics, including sleep-heart rate variability (HRV), stress levels, and offers an Emotional Wellbeing Assistant. Huawei first launched this smart band in select global markets earlier this year in February. The Huawei Band 10 is priced at Rs. 6,499 for the polymer case model and Rs. 6,999 for the aluminium alloy variant in India. The company has announced a launch offer valid until June 10, which will reduce the prices to Rs. 3,699 and Rs. 4,199, respectively. Customers can buy both variants exclusively on Amazon. The polymer case is available in Black and Pink, while the aluminium alloy models come in Blue, Green, Matte Black, Purple, and White colours. Also read: WWDC 2025: How to Watch Apple's Live Event and What to Expect from iOS 26, AI Tools and More The Huawei Band 10 features a 1.47-inch AMOLED rectangular display with Always On Display support, which aims to offer users clear visibility of essential information. It includes touch and swipe controls along with a side button for navigation. The screen resolution stands at 194×368 pixels with a pixel density of 282ppi. Also read: Google pauses 'Ask Photos' AI Feature to address performance issues In terms of health tracking, the Huawei Band 10 measures key metrics such as sleep-heart rate variability (HRV), stress levels, and blood oxygen saturation (SpO2). It also includes optical heart rate monitoring and an Emotional Wellbeing Assistant. This assistant delivers wellness tips and offers calming or positive watch face suggestions. The band supports inbuilt breathing exercises to help users manage stress. Also read: Adobe launches the Photoshop Beta app for Android smartphones: Everything you need to know Furthermore, the device comes with 100 preset workout modes, which cover activities like running, cycling, yoga, and swimming. The Band 10 includes an accelerometer, gyroscope, and magnetometer to enhance activity tracking. Notably, the smart band targets swimmers by offering a 95 percent accuracy rate in swim stroke and lap detection. It achieves this through a nine-axis sensor combined with AI-based stroke recognition. The band also holds a 5ATM water resistance rating and supports both Android and iOS platforms. Mobile finder: iPhone 16 LATEST price, specs and all details
New Indian Express
an hour ago
- New Indian Express
Tube-net seaweed farming takes root along AP coast
VISAKHAPATNAM: Seaweed farming is gaining popularity along Andhra Pradesh coast as an emerging livelihood, and sustainable marine practice that boosts coastal productivity. Known as the 'Medical Food of the 21st Century', seaweed offers health benefits, and industrial uses ranging from pharmaceuticals to food additives. Despite its potential, commercial seaweed farming in India's open seas remains limited due to strong wave action and environmental factors. Traditional bamboo raft-based mono-line farming, suitable for shallow, calm waters, often fails in rougher coastal areas. To overcome this, scientists have developed a tube net-based farming method using floating high-density polyethylene (HDPE) rafts with a multipoint mooring system. Speaking to TNIE, Joe K Kizhakudan, Principal Scientist and Head of ICAR-CMFRI's Visakhapatnam Regional Centre, said this system has shown structural stability and better yield in turbulent waters up to 10 metres deep. Trials using Kappaphycus alvarezii off Visakhapatnam coast proved successful. Under the Pradhan Mantri Matsya Sampada Yojana (PMMSY), the government has promoted this system, establishing a unit in Budagatlapalem village in Srikakulam district. Subsidies are being provided to Self-Help Groups (SHGs) and fisher communities. Seaweed is harvested every 45 days, with dry seaweed selling for Rs 80 to Rs 90 per kg. Ten kg of wet seaweed yields 1 kg of dry product. The required tubes last up to 10 years, making the model sustainable with low recurring costs.
Indian Express
2 hours ago
- Indian Express
High costs of life-saving drugs leave patients of rare diseases in the lurch: Will their crusade for Indian variants win?
For Seba P A, 26, from Kerala, the cost of breathing easy, moving around and enduring fewer bouts of infection comes at a steep price — nearly Rs 18 lakh per month. For long, she had managed with the Rs 50 lakh government grant under the national policy of rare diseases, one of which — Spinal Muscular Atrophy — she is battling. Now she is on a crusade to make life-saving drugs, currently under patents, affordable for persons suffering from rare diseases. Suffering from Spinal Muscular Atrophy (SMA), a rare disease that progressively affects muscle functions, her condition can be managed with Risdiplam. Developed by Swiss pharma giant Roche, one bottle of Risdiplam costs around Rs 6 lakh in India — something her taxi driver father cannot afford. In a bid to make the life-altering medicine affordable for SMA patients like herself, Seba had in December 2023 filed a petition in the Kerala High Court urging the government to invoke the compulsory licensing clause under Section 84 of the Indian Patents Act, 1970. This allows the Indian government to grant someone other than the patent holder the right to make the medicine if a product or process is nationally unavailable or overpriced. Roche holds the patent for Risdiplam till May 2035. Her case is now being heard in the Supreme Court. 'If other companies start manufacturing the drug, the prices are likely to plummet,' says Seba. Like her, patients suffering from rare diseases, who need life-long therapy, have been urging the government to invoke the compulsory licensing clause. WHY PATIENTS OF RARE DISEASES RAN OUT OF OPTIONS Two years ago, Seba's family had applied for financial aid under the Centre's National Policy for Rare Diseases, 2021, which had identified 1,000 patients, including Seba, for a one-time financial assistance of Rs 50 lakh each. 'When I was taking Risdiplam, my health was stable. I was able to speak and sing. However, the funds got exhausted in mid-February. Since then, I have already had two bouts of infections and have been confined to bed,' Seba, who loves singing and painting, tells The Indian Express. Though she is back on Risdiplam, being provided by Roche free of cost for a year while the case is on, it continues to be out of reach to other SMA patients. The mother of a 14-year-old boy from Bengaluru has been struggling to obtain medicine to treat his cystic fibrosis (CF), a genetic condition that affects cells that produce mucus, sweat and digestive juices, making them thick and sticky, clogging up lungs and the digestive system. In 2019, Trikafta, a three-drug combination sold by US-based Vertex, was approved by the US Food and Drug Administration (FDA) for CF treatment. 'Importing a three-month supply costs Rs 70 lakh. An Argentina company manufactures a slightly cheaper version that costs around Rs 21 lakh for a three-month supply,' she says. She is one of the petitioners urging the government to grant a compulsory license for the medicine. In an attempt to get the medicine from Argentina, the mother scours Facebook for Indians living there and requests them to get the medicine when they come home. 'I split the tablets to make them last at least six months. If Indian companies are given compulsory licences, I might be able to afford medicines for my son,' she says. WHAT'S THE STATUS OF COMPULSORY LICENSING CLAUSE? Despite the exorbitant cost of drugs used to manage rare diseases, India's compulsory licensing clause has been used just once in 20 years. 'Only one private company got a compulsory license once,' says Anand Grover, a senior lawyer who works on such patent cases, referring to the New Delhi-based Natco Pharma, which secured the permit to manufacture Nexavar, a cancer drug made by German multinational Bayer, in 2012. Since then, three Indian companies have unsuccessfully applied for compulsory licences — BDR Pharmaceuticals for Dasatinib (for leukemia), Lee Pharma for Sitagliptin (for diabetes), and Emcure Pharmaceuticals for Trastuzumab (for breast cancer), says Sneha Sharma, a partner at Sujata Chaudhri IP Attorneys. ROCHE VS NATCO In 2024, Roche Pharmaceuticals had filed a petition to get an injunction, claiming that Natco Pharmaceutical was in the process of launching a generic version of Risdiplam. Though its injunction was denied by the Delhi High Court in March 2025, the Swiss drug-maker has filed an appeal. The Division Bench has heard the arguments in the case and is now awaiting written statements from both parties. Meanwhile, Natco announced that if it is allowed to manufacture and market the generic version of Risdiplam, it will sell it for just Rs 15,900 per bottle (against Roche's Rs 6 lakh per bottle). Though Roche's assistance programme provides five bottles at the cost of two, patients still end up spending nearly Rs 30 lakh annually. A generic version of Risdiplam would mean that the government's Rs 50-lakh aid will last almost nine years instead of just a few months for SMA patients. Risdiplam is sold for around $500 (around Rs 42,000) per bottle in China and Pakistan. 'Risdiplam costs less in China and Pakistan where prices were negotiated with the company. Since that did not happen in India, a simple solution would be to issue a compulsory license to Natco,' says Grover. He also challenged the narrative put forth by the Swiss drug-maker, which said that a drug's exorbitant prices were meant to cover the 'high costs' of research and development (R & D). In its suit against Natco, Roche had said that it takes a company nearly 10-15 years and an estimated $2.6 billion (nearly Rs 260 crore) to bring a successful drug to the market. The company had claimed that only one in nearly 5,000 or 10,000 drugs in the research pipeline and around 12% of those in clinical trials get approved. 'Many drugs are, in fact, developed by smaller companies that are acquired by bigger ones and taken to clinical trials. Big companies often hold these patents despite not bearing initial costs of developing several candidate drugs. The figures these companies have been giving out for years are an exaggeration. Which is why we ask for actual costs the companies incur on drug R & D,' says Grover. He says studies have shown that the cost of developing Risdiplam would, at most, be $150 million, a figure that has not yet been contested by the company. HOW PHARMA MAJORS PROLONG PATENT CONTROL Pharma giants find loopholes to prolong their control over a drug. When it comes to Trikafta, the CF drug, Vertex Pharmaceuticals already holds the patent for two of these medicines in India while an application for the third is in process. 'In a blatant abuse of its monopoly, Vertex has filed and obtained multiple patents in India, thus having monopoly rights on various CFTR modulators (a class of medications designed for individuals with CF). But it has not bothered to register the medicine in India,' states a 2024 petition by CF patients in the Karnataka High Court. Sharma says a compulsory licence may also be issued if a patent holder has not worked the patent in over three years. PATENTING PHARMACEUTICALS IN INDIA When the country's new patent law was brought out in the 1970s, the government created a very important provision — it allowed for only process patenting when it came to pharmaceuticals. 'After the British left, drugs in India were very costly. A committee set up by (then PM) Mrs (Indira) Gandhi recommended dropping product patenting for pharmaceuticals. If a product is patented, you cannot do anything. But if a process is patented, you can legally make a similar drug using another process. That is what was done under the new Patent Act that came into force in 1972,' says Grover. This decision was key to the generic manufacturing of pharmaceuticals in India, earning the country the moniker of the 'pharmacy of the world.' Meanwhile, the US, which wanted to create a monopoly for itself, forced the world to accept the Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement, which came into effect on January 1, 1995. While countries like Brazil, Mexico and India initially formed a block against TRIPS, threats of sanctions forced them to toe the line. India was given time till 2005 to implement provisions similar to the ones in the US — ensuring product patents and extending patent period from seven to 20 years, explains Grover. In fact, India's Patent Act, which allowed only the process to be patented, became the reason why Indian drug-maker Cipla could establish itself as the 'Robin Hood' of pharmaceuticals. In 2001, the company started selling a cocktail of antiretrovirals (medicines used to manage HIV) for less than $1 a day, driving down the prices of the medication across the world. Grover says, '(Despite TRIPS), we still tried to maintain some provisions that would help our people. Our law does not allow extending patents simply by changing the medicine's form or replacing some salts (a process called ever-greening of patents) unless there is a significant change in its efficacy. Our law also allows for both pre and post-grant opposition.' Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
